Home Cart Sign in  
Chemical Structure| 105816-04-4 Chemical Structure| 105816-04-4

Structure of Nateglinide
CAS No.: 105816-04-4

Chemical Structure| 105816-04-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nateglinide is an insulin secretagog agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).

Synonyms: A4166; Senaglinide; Starlix

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nateglinide

CAS No. :105816-04-4
Formula : C19H27NO3
M.W : 317.42
SMILES Code : O=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O
Synonyms :
A4166; Senaglinide; Starlix
MDL No. :MFCD00875706
InChI Key :OELFLUMRDSZNSF-OFLPRAFFSA-N
Pubchem ID :5311309

Safety of Nateglinide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H361
Precautionary Statements:P201-P202-P264-P270-P281-P301+P312-P308+P313-P330-P405-P501

Isoform Comparison

Biological Activity

Target
  • Potassium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
BRIN-BD11 cells 100 μM 18 h 18-hour exposure to 100 mM nateglinide abolished the acute insulinotropic effects of nateglinide, tolbutamide, and glibenclamide, but did not affect the insulinotropic effect of efaroxan. Br J Pharmacol. 2004 May;142(2):367-73.
BRIN-BD11 cells 10–400 μM 20 min Nateglinide induced a concentration-dependent increase in insulin release at non-stimulatory glucose concentrations and evoked K ATPchannel-independent insulin secretion in depolarized cells. Br J Pharmacol. 2004 May;142(2):367-73.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Streptozotocin (STZ)-induced diabetic mice Oral 150 mg/kg Every 3 days for 130 days To evaluate the effectiveness of Ins@Alg/NG in regulating blood glucose levels in diabetic mice, results showed that Ins@Alg/NG significantly reduced blood glucose levels and restored pancreatic function. Adv Sci (Weinh). 2023 Oct;10(29):e2301879

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03492580 - Completed - United States, New Jersey ... More >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 Less <<
NCT02456428 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02475499 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02476760 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02616666 Type 2 Diabetes Mellitus Phase 4 Recruiting December 31, 2021 -
NCT01456130 Diabetes Mellitus Phase 3 Completed - Japan ... More >> Nagoya-shi, Aichi, Japan Fukuoka-shi, Fukuoka, Japan Kurume-shi, Fukuoka, Japan Sapporo-shi, Hokkaido, Japan Kobe-shi, Hyogo, Japan Kagoshima-shi, Kagoshima, Japan Kumamoto-shi, Kumamoto, Japan Osaki-shi, Miyagi, Japan Minou-shi, Osaka, Japan Osaka-shi, Osaka, Japan Kamio-shi, Saitama, Japan Koshigaya-shi, Saitama, Japan Adachi-ku, Tokyo, Japan Chuo-ku, Tokyo, Japan Less <<
NCT01697592 Type 2 Diabetes Mellitus Phase 3 Completed - -
NCT01919489 Type 2 Diabetes Phase 4 Recruiting June 2019 United States, Florida ... More >> University of Miami Recruiting Miami, Florida, United States Contact: Gianluca Iacobellis, MD       GIacobellis@med.miami.edu    Principal Investigator: Gianluca Iacobellis, MD          United States, Georgia Grady Memorial Hospital Recruiting Atlanta, Georgia, United States, 30303 Contact: Guillermo E Umpierrez, MD    404-778-1665    geumpie@emory.edu    Contact: Francisco J Pasquel, MD    404 778 1697    fpasque@emory.edu    Principal Investigator: Guillermo Umpierrez, MD          Sub-Investigator: Francisco J Pasquel, MD          Sub-Investigator: Priya Vellanki, MD          Emory University Hospital Recruiting Atlanta, Georgia, United States, 30324 Contact: Francisco Pasquel, MD       fpasque@emory.edu    Sub-Investigator: Francisco Pasquel, MD          Emory Universtiy Hospital at MIdtown Recruiting Atlanta, Georgia, United States Contact: Francisco Pasquel, MD          Sub-Investigator: Rodolfo J Galindo, MD          United States, New York State University of NY at Buffalo Recruiting New York, New York, United States Contact: Ajay Chaudhuri, MD       AChaudhuri@KaleidaHealth.Org    Principal Investigator: Ajay Chaudhuri, MD Less <<
NCT02143765 Type 2 Diabetes Mellitus Phase 4 Completed - China, Jiangsu ... More >> The First People's Hospital of Changzhou Changzhou, Jiangsu, China The Second People's Hospital of Huai'an Huai'an, Jiangsu, China Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University Nanjing, Jiangsu, China Xuzhou Central Hospital Xuzhou, Jiangsu, China Yancheng City No.1 People's Hospital Yancheng, Jiangsu, China Zhenjiang First People's Hospital Zhenjiang, Jiangsu, China Less <<
NCT01697592 - Completed - -
NCT00212290 Insulin Resistance ... More >> Type 2 Diabetes Mellitus Less << Phase 4 Completed - United States, Washington ... More >> VA Puget Sound Health Care System (Seattle Campus) Seattle, Washington, United States, 98108 VA Puget Sound Health Care System (American Lake Campus) Tacoma, Washington, United States, 98493 Less <<
NCT00259168 Insulin Resistance|Impaired Fa... More >>sting Glucose Less << PHASE4 COMPLETED 2025-03-06 Endothelial laboratory, Cardio... More >>logy clinic Y-research, H:S Bispebjerg Hospital, Bispebjerg Bakke, Copenhagen, Copenhagen NV, 2400, Denmark Less <<
NCT00461617 Diabetes Phase 3 Completed - -
NCT00369148 Type 2 Diabets Mellitus Phase 4 Completed - Japan ... More >> Nippon Kokan Hospital Kawasaki, Kanagawa, Japan, 210-0852 Hamamatsu Red Cross Hospital Hamamatsu, Shizuoka, Japan, 430-0907 Saiseikai Central Hospital Minato-ku, Tokyo, Japan, 108-0073 Kitasato Institute Hospital Minato-ku, Tokyo, Japan, 108-8642 Keio University Hospital Shinjuku-ku, Tokyo, Japan, 160-8582 Tokyo Metropolitan Ohtsuka Hospital Toshima-ku, Tokyo, Japan, 170-8476 Less <<
NCT01456130 - Completed - -
NCT00189774 Type 2 Diabetes Mellitus ... More >> Diabetes Mellitus, Type II Less << Phase 2 Phase 3 Completed - Japan ... More >> Chubu region, Japan Chugoku region, Japan Hokkaido region, Japan Kanto region, Japan Kinki region, Japan Kyushu region, Japan Tohoku region, Japan Less <<
NCT00437918 Diabetes Mellitus ... More >> Type 2 Diabetes Mellitus Less << Phase 4 Completed - Korea, Republic of ... More >> Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University Busan, Korea, Republic of, 614-735 Endocrinology and Metabolism, Maryknoll General Hospital Busan, Korea, Republic of Less <<
NCT03283358 Intermittent Claudication Not Applicable Recruiting December 31, 2020 Sweden ... More >> Department of Surgery, Unit of Vascular Surgery, Södersjukhuset Recruiting Stockholm, Sweden, SE-11883 Contact: Sara Haile, RN    +46 8 6162462    sara.haile@sodersjukhuset.se    Principal Investigator: Anneli Linné, MD, PhD          Karolinska University Hospital, Dept of Vascular Surgery Recruiting Stockholm, Sweden Contact: Ulrika Palmer Kazen, MD, PhD    08-51770000       Principal Investigator: Ulrika Palmer Kazen, MD, PhD Less <<
NCT00097786 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT00238472 Diabetes Mellitus, Type 2 Phase 4 Completed - -
NCT00319189 Renal Transplant Recipients|Po... More >>sttransplant Diabetes Mellitus|Posttransplant Impaired Glucose Tolerance Less << PHASE4 COMPLETED 2025-11-03 Rikshospitalet, Section of Nep... More >>hrology, Oslo, 0027, Norway Less <<
NCT01030952 - Completed - -
NCT00402909 Type 2 Diabetes PHASE4 COMPLETED 2025-08-07 Novartis Pharmaceuticals, East... More >> Hanover, New Jersey, 07974, United States Less <<
NCT00928889 Diabetes Mellitus, Type 2 Phase 4 Completed - China ... More >> People's Liberation Army. The Military General Hospital of BeiJing BeiJing, China, 100020 Peiking University First Hospital BeiJing, China, 100034 Chinese PLA General Hospital Beijing, China, 100853 The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University Guangzhou, China, 510080 The Second Affiliated Hospital, Zhongshan (Sun Yat-sen) University Guangzhou, China, 510120 Nanfang Hospital, the Affiliated South Hospital of the Southern Medical University Guangzhou, China, 510515 Less <<
NCT00097786 - Completed - -
NCT02088918 Healthy Volunteers Phase 1 Completed - Korea, Republic of ... More >> Chungnam University Hospital Daejeon, Korea, Republic of Less <<
NCT00928889 - Completed - -
NCT00858013 Type 2 Diabetes Mellitus Phase 4 Completed - Korea, Republic of ... More >> Myongji Hospital Ilsan, Kyounggi, Korea, Republic of Hanyang University Medical Center Guri-si, Kyunggi-do, Korea, Republic of Inha University Hospital Incheon, Korea, Republic of Hallym University Medical Center Seoul, Korea, Republic of Korea University Guro Hospital Seoul, Korea, Republic of Kyung hee University Medical Center Seoul, Korea, Republic of Ajou University Hospital Suwon-si, Korea, Republic of Less <<
NCT01030952 Diabetes Mellitus, Type 2 Phase 4 Completed - China ... More >> Sir Run Run Shaw Hospital, 3 East Qingchun Road Hangzhou, China, 310016 Shanghai Tongji Hospital, 389 Xinchun Road Shanghai, China, 200065 Shanghai Sixth People's Hospital, 600 Xuanshan Road Shanghai, China, 200233 Less <<
NCT01159158 Healthy PHASE1 COMPLETED 2025-02-07 -
NCT01160029 Healthy PHASE1 COMPLETED 2025-10-04 -
NCT01316107 Type 2 Diabetes Mellitus Phase 3 Completed - Japan ... More >> Hokkaido, Japan Kantou, Japan Kyushu, Japan Touhoku, Japan Less <<
NCT00858013 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.15mL

0.63mL

0.32mL

15.75mL

3.15mL

1.58mL

31.50mL

6.30mL

3.15mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories